- Werewolf Therapeutics, Inc. reported a **net loss of $16.4 million** for the third quarter of 2025 and held **$65.7 million in cash and cash equivalents** as of September 30, 2025, which is expected to fund operations into the **fourth quarter of 2026**.  **[1785530_0001785530-25-000030_a09302025ex991.htm:2]** 
- The company received **Fast Track Designation** from the US FDA for WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma.  **[1785530_0001785530-25-000030_a09302025ex991.htm:1]** 
- Updates on the **WTX-124 Phase 1/1b clinical trial** interim data and feedback from an End of Phase 1 meeting with the FDA, as well as an update on the **WTX-330 Phase 1b/2 clinical trial**, are anticipated in the **fourth quarter of 2025**.  **[1785530_0001785530-25-000030_a09302025ex991.htm:0]** **[1785530_0001785530-25-000030_a09302025ex991.htm:1]** 
- **WTX-1011**, the company's first INDUCER T-cell engager development candidate, continues IND-enabling studies, with a plan to nominate a differentiated target candidate by **year-end 2025**.  **[1785530_0001785530-25-000030_a09302025ex991.htm:0]** **[1785530_0001785530-25-000030_a09302025ex991.htm:1]**

Werewolf Therapeutics (HOWL)